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Introduction. Overdose with the calcium channel blocker amlodipine can cause profound hypotension that may be exacerbated by
theconcurrentingestionofanangiotensinIIreceptor antagonist.Bestmanagementofsuchoverdosesisuncertain althoughtheuse
of hyperinsulinaemia-euglycaemia (HIE) has been recommended. Case report. Wereport a case of mixed amlodipine and losartan
overdose in a 50-year-old lady. Severe hypotension was resistant to conventional vasopressors and high-dose insulin/euglycaemia,
but did respond to a metaraminol infusion. Conclusion. A trial of metaraminol early in severe cases of calcium channel blocker
and angiotensin II receptor antagonist toxicity may be of beneﬁt, especially when conventional ionotropic treatment measures are
failing.
1.Introduction
Severe calcium-channel blocker overdose of the dihydropy-
ridine class has a profound eﬀect on the systemic vascular
resistance. Of the dihydropyridine class, amlodipine is often
favoured for its once daily dosing, lackof negative ionotropy,
and prolonged duration of eﬀect (which can last up to
72 hours) [1]. Conventional treatment of calcium channel
blocker overdose centres on increasing transmembrane cal-
cium ﬂow either by increasing extracellular calcium concen-
tration or by increasing intracellular cAMP concentration,
which can be achieved by adenylate cyclase stimulation
(adrenaline or glucagon) or phosphodiesterase inhibition
(amrinone, milrinone) [2]. However, no controlled trails
have been conducted, and treatment successes or failures
have been reported in almost equal measure [3–8].
Angiotensin II receptor blockers (in this case Losartan)
bind at the AT1 receptor and inhibit vasoconstriction,
sympathetic activation, peripheral noradrenergic transmis-
sion, baroreceptor desensitisation, endothelin release, renal
sodium reabsorption, adrenal cortical aldosterone release,
and nitrous oxide destruction [9, 10].
The combination of an angiotensin II receptor blocker
and a calcium channel blocker could produce a synergistic
toxicity by limiting the eﬀectiveness of both endogenousand
exogenously administered catecholamines [11].
Treatment for a mixed overdose in these patients have
included: intravenous ﬂuid guided by central venous pres-
sure, calcium chloride/gluconate boluses/infusion, glucagon
boluses or infusion, atropine, isoprenaline, high dose nora-
drenaline/adrenaline, vasopressin/terlipressin, haemoperfu-
sion, hyperinsulinaemia-euglycaemia, and intralipid. [3–8,
11–17].
Hyperinsulinaemia-euglycaemia in the treatment of
severe calcium channel blocker overdose is not without
controversy. Its eﬀectiveness has never been rigorously
established [14]. It has been proposed that failure of
hyperinsulinaemia-euglycaemia in severe calcium channel
blocker overdose has sometimes been due to inadequate
dosing and speed of starting treatment [2, 14].2 Case Reports in Medicine
To our knowledge, only one previous case of severe
calcium channel blocker and angiotensin II receptor blocker
overdose has been reported in the literature; this reported
success with hyperinsulinaemia-euglycaemia, although the
data in the paper’s ﬁgures is not convincing [11]. We
report a case of severe mixed amlodipine and losartan
overdose causing refractory hypotension resistant to all con-
ventional vasopressors and hyperinsulinaemia-euglycaemia,
but responsive to a metaraminol infusion.
2.CaseReport
A 50-year-old lady presented to the emergency department
(ED) having called the ambulance herself. She reported
takinganoverdose(handfulsoftablets)ofherbloodpressure
tablets 2h45min previously. The empty packets that she
brought with her equated to 104 × 160mg of losartan
(16,640mg) and 77 × 10mg of amlodipine (770mg). She
had a past medical history of type 2 diabetes mellitus,
hypertension, and morbid obesity (weight 137kg).
Atpresentation, her airway waspatent, with a respiratory
rate of 14 breaths/minute and SpO2 of 93% in room air,
pulse 100beats/minute, blood pressure 122/61mmHg, and
temperature36.4◦C, with GlasgowComa Scoreof15/15.Her
ECG was normal.
Her initial laboratory results revealed a normal full
blood count (FBC), normal renal function including normal
potassium, normal liver function tests, and a blood glucose
of 10.6mmol/litre.
Shortly after initial assessment in the ED, her blood
pressure dropped rapidly to 70/40mmHg with a pulse of
90beats/minute that was unresponsive to resuscitation with
2 litres of IV ﬂuid. A central venous line was inserted,
and she was transferred to Medical High Dependency. A
further 3 litres of intravenous ﬂuid were administered,
but she remained anuric and her blood pressure remained
at 75mmHg systolic (mean arterial pressure (MAP) 45–
50mmHg (see Table 1 and Figures 1 and 2). An arterial line
was inserted.
Five hours after presentation in the ED, an infusion of
noradrenaline (0.1mcg·kg−1·min−1) the maximum allowed
on High Dependency, was started. As this was being setup,
metaraminol (boluses of 0.5mg) were administered produc-
ing a transient increase in MAP (Table 1, Figure 2). She also
received 20mLs of 10% calcium gluconate. At this time,
pulmonary oedema was seen on X-ray and hypoxia noted
(SpO2 91% on FiO2 of 60%). She was started on noninvasive
ventilation (NIV) with improvement in oxygenation. Her
cognitive function remained normal throughout with a GCS
of 15.
Advice from the UK National Poisons Information
Service at this time was to: give further calcium and
start an infusion, try glucagon, continue to uptitrate the
ionotropes and consider terlipressin or vasopressin, and
to start hyperinsulinaemia-euglycaemia therapy (1unit/kg
bolustheninfuseat0.5units/kg/hr,increasingtoamaximum
of 10units·kg−1·hr−1).
Glucagon was given as a bolus of 10mg followed by an
infusion once the patient arrived on ICU. The ﬁrst bolus did
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Figure 1: Haemodynamic parameters over the intensive care
period.
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Figure 2: Response of MAP in mmHg to infusions over the
intensive care period. Note: left y-axis MAP in mmHg, right y-
axis infusions of ionotropes in mcg·kg−1·min−1.A r r o w ss h o w
metaraminol boluses.
appear to improve the MAP to above 80mmHg in much the
same way as the metaraminol had; however, this was also
transient and caused severe vomiting.
She was transferred to intensive care 11 hours after
presentation to the ED where she was started on vaso-
pressin and the noradrenaline was uptitrated initially to
0.05mcg·kg−1·min−1 andthen0.29mcg·kg−1·min−1 within
the ﬁrst hour with continued increases over the day. Due to
a lack of response, adrenaline was also added along with a
calcium infusion (Figure 2).
Hyperinsulinaemia-euglycaemia was started at 14 hours
after admission; after a bolus, the infusion was increased to
6U·kg−1·hr−1 over the next 12hrs without any sustained
improvement in blood pressure, although there was a slightCase Reports in Medicine 3
Table 1: Initial eﬀect of metaraminol boluses.
Time since admissionto ED in hours Metaraminol
bolus of 0.5mg
Systolic Diastolic MAP Pulse
In ED 122 61 81 100
In ED 1 hour after admission 70 40 50 90
Taken from medical SHO clerking 3 hours
after admission
75 43 54 96
5 when ﬁrst seen by ICU 80 50 63 98
5 given metaraminolin boluses at intervals
of 5–10 minutes. 0.5mg + 0.5mg 72 46 55 99
5:20 110 68 82 89
5 then given calcium gluconate (20mLs of
10%) followed by glucagon 10mg as a bolus 0.5mg + 0.5mg 125 62 84 100
5:30 120 74 89 86
6 90 50 63 85
7 noradrenaline started here 70 48 55 85
8 75 43 54 85
9 80 48 59 85
10 90 55 67 85
11—admitted to ICU- vasopressinstarted
here along with glucagons infusion
85 47 60 95
12 adrenaline started here 95 50 65 80
Table 2: Initial blood gas results.
Time since admissionto ED in hours pH BE Bicarbonate PCO2 PaO2 Lactate
In ED venous gas recorded 7.371 −2.3
5h o u r sp o s tE D 7.3 −3.9 21 7.49 7.9
11:25—on trauma mask 7.34 −6.2 19.3 4.84 9.37 1.79
12:00—now on NIV 7.36 −5.8 19.5 4.52 7.83 2.5
13:00 7.3 −9.4 16.8 4.49 9.56 2.5
17:00 7.26 −10.4 16 4.7 9.43 6.44
18:00 7.27 −10.3 16.1 4.54 8.26 5.87
19:30 7.26 −11.2 15.5 4.5 10.00 6.25
20:54—bicarbonate started on basis of this
gas—50mLs/hr of 8.4%
Total 200mLs given
7.25 −13.3 14 3.95 10.89 7.78
22:54 7.31 −10.1 16.2 3.93 7.83 6.27
23:57 7.32 −8.0 17.9 4.53 9.47 4.23
25:00 7.35 −6.2 19.3 4.51 8.58 3.63
26:06 7.34 −6.0 19.5 4.96 10.08 2.89
27:01 7.33 −5.8 19.7 4.91 9.73 2.40
28:26 7.33 −5.7 19.7 4.97 9.64 2.05
29:32 7.34 −5.1 20.1 4.95 9.11 1.77
rise in MAP over the initial period. At 14hrs after admission
to the ED, she was administered 150mL bolus of intralipid
20% over 5min and an infusion of 3mL·kg−1·hr−1 was then
started (650mL givenin total).Twenty hours after admission
to the ED, sodium bicarbonate (200mLs of 8.4%) was
administered;againwithoutresponsehaemodynamically but
with an improvement in the acid base status. By this point,
she had a severe metabolic acidosis (see Table 2).
At this time (18hrs after presentation to ED, Figures 1, 2,
4,a n d5), she was refractory to vasopressin (0.02units·hr−1),
adrenaline (0.24mcg·kg−1·min−1),noradrenaline (0.29mcg·
kg−1·min−1),glucagon(0.12unitshr−1),hyperinsulinaemia-
euglycaemia (800unitshr−1), and calcium (3mL·kg−1·hr−1
of 10%). She remained anuric and her renal function
was deteriorating (peak creatinine 231mmol·l−1 and urea
14.6mmol·l−1) (at 48hrs after admission to ED)4 Case Reports in Medicine
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Figure 3: MAP after starting metaraminol infusion (hours 38–
66). Note left y-axis MAP in mmHg, right y-axis metaraminol in
mcg·kg−1·min−1. Arrows show metaraminol boluses.
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Figure 4: The eﬀect of hyperinsulinaemia-euglycaemia on MAP.
The patient was started on a metaraminol infusion 46-
47hrs after admission to ED following a discussion with
the team about her initial response to the drug. There was
an immediate striking response, the MAP increasing from
below 70mmHg to more than 80mmHg for the ﬁrst time
since admission (aside from the boluses given at 5 hours),
butevenmore striking was the change in urine outputwhich
increased dramatically (Figure 5). The eﬀect of metaraminol
permitted the other ionotropes to be weaned over the
next few hours (Figure 2). Her urine output improved but
she developed hyperkalaemia (6.3mmol·l−1)—a likely side
eﬀect of hyperinsulinaemia-euglycaemia therapy cessation.
She made a slow recovery and was discharged to Medical
HighDependency6daysafteradmission. Shewasdischarged
from hospital, after psychiatric input, shortly afterwards.
3.Discussion
This is the ﬁrst case report of severe calcium channel
blockerandangiotensinIIreceptorblockeroverdosethatwas
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Figure 5: The eﬀect of metaraminol on urine output.
successfully treated with a metaraminol infusion where other
treatment options failed or had not been tried. The only
other case report in the literature did not use metaraminol
by infusion, as the drug was not available to them. Direct
personal communication with the lead author conﬁrmed
this [11]. The paper by Wood et al. which successfully used
metaraminol did not use hyperinsulinaemia-euglycaemia at
all and the overdose, although mixed, had a much lower
(120mg)doseofanangiotensinconvertingenzyme inhibitor
compared with the 16.6g of the angiotensin II receptor
blocker that the patient in our case had ingested [4].
Hyperinsulinaemia-euglycaemia appears to work by
allowing theswitch ofcellularmetabolism fromfatty acidsto
carbohydrates that is required in stress conditions, especially
in the myocardium and vascular smooth muscle, resulting
in an improvement in cardiac contractility and restored
peripheral resistances [2].
Most of the current evidence around hyperinsulinaemia-
euglycaemia (from the various case reports quoted) seems to
suggestthatstartingitearlyiscrucialtoitssuccess.Westarted
it within 14 hours. There is not a consistent time frame in
the literature that constitutes early administration. However,
as described in a couple of other case reports, we found
that it had little eﬀect [12, 15]; however, there was perhaps
a transient increase at the start when we were infusing 800
units per hour; however, multiple infusions were initiated
between 11 and 16 hours so it is diﬃcult to attribute this to
the hyperinsulinaemia-euglycaemia and the ionotropes were
greatly uptitrated during this period (Figure 4).
In ourcase, we did howeverﬁnd thatkeepingup with the
blood sugar was problematic and dangerous. Large amounts
of glucose were required with intensive nursing care to
prevent hypoglycaemia. We found that the glucose suddenly
dropped over the space of 3 minutes between checks after a
long period of not changing consistent with the reported 40
minutesorso forthehyperinsulinaemia-euglycaemia tostart
working. Previous case reports and reviews have mentioned
the low side eﬀects of hyperinsulinaemia-euglycaemia mak-
ing it an attractive option [2].Case Reports in Medicine 5
It was unclear why glucagon appeared to have a transient
eﬀect in our case. It did, however, cause severe vomiting.
Vomiting is a well-documented side eﬀect of glucagon,
particularly in high doses as given in this case.
Intralipid was also tried. Due to amlodipine being highly
lipophilic, it would seem plausible that intralipid would
work to bind it. Young et al. reported a case of verapamil
overdose that resulted in cardiac arrest that was successfully
treated with intralipid [18]. We could not ﬁnd any othercase
reports of signiﬁcant calcium channel blocker/angiotensin
II receptor blocker overdose where intralipid was used but
TOXBASE advises that “If life threatening arrhythmias (e.g.,
ventricular tachycardia, ﬁbrillation, heart block, and asys-
tole) are unresponsive to the above consider the use of a lipid
emulsion (e.g., 1mL/kg of 20% intralipid as an intravenous
bolus followed by 3mL/kg/hour to an initial maximum of
500mL lipid in an adult).” This did not appear to have
any clinical eﬀect. It is unclear if it would have been more
eﬀective if it had been given earlier in the clinical course.
There is weak evidence for the use of intralipid in verapamil
overdose [16]. However, overall the evidence for the use of
intralipid in overdose is limited to case reports and animal
studies and although promising results have been reported
the current guidance for its use is limited to individual
agents.Forexample,theAssociationofAnaesthetistsofGreat
Britain and Northern Ireland (AAGBI) recommend its use
for local anaesthetic toxicity, perhaps the group of drugs
where the greatest body of anecdotal evidence exists.
4.Why Did Metaraminol WorkWhen
All ElseFailed?
It is unclear why a synthetic, predominantly alpha-agonist
(metaraminol) should have such a profound eﬀect when
other agents with alpha-1 eﬀects, most notably nora-
drenaline did not seem to. Whether it is the mechanism
of action, a direct alpha agonist and an indirect alpha
and beta agonist (via noradrenaline and adrenaline), or
whether it has a property that has not yet been elucidated
is speculative. The end product of metaraminol and other
predominantly alpha-1 agents is calcium, but this is due to
inositol triphosphate (which can act extracellularly), due to
an increase in phospholipase C rather than from increased
cAMP that results from adrenaline or noradrenaline. This
additional pathway may go some way to explain why
metaraminol worked.
It has been recognised that pure alpha agonists such
as phenylephrine and methoxamine have a role in the
management of anaphylaxis where adrenaline has failed to
have an eﬀect. Most notably in a case of anaphylaxis during
open cardiac surgery where the ionotropic and chronotropic
eﬀects were visible to the authors but the lack of SVR and
underﬁlling meant that phenylephrine was crucial to the
successful management of the patient [19].
Another reason why metaraminol may have worked
where other agents did not is the possibility of dynamic
left ventricular outﬂow obstruction. The diagnosis in critical
care is important as reducing catecholamines and adding
vasopressing agents may actually improve the situation [20].
The metaraminol infusion was started later in the course
of this case, and it could be proposed that the eﬀect of the
calciumchannel blockerand angiotensinII receptorblockers
were wearing oﬀ by this time. Once-daily administration of
losartan is possible because the drug’s eﬀects are extended
by the EXP-3174 metabolite (which has a half-life of 6–9
hours), which is 40 times more potent than losartan and
has been found to produce consistent reductions in blood
pressure over a 24-hour period. [21] However, the half-life
of amlodipine is 35–50 hours although the eﬀects can persist
for signiﬁcantly longer [1]. A striking change was seen when
metaraminol was given at the very start of the case (Table 1)
andthenagainwhenitwasblousedandstartedasaninfusion
(Figures 2 and 3). The patient was weaned from all other
ionotropes within 2 hours (Figure 2).
Conventional methods have often failed to improve
haemodynamics in severe overdoses of this kind and
Lheureux mentions in his excellent review that people have
resorted to extreme measures such as intra-aortic balloon
counterpulsationand extracorporeal circulatorysupport [2].
We propose a less extreme measure (the use of metaraminol
by infusion) that is readily available and relatively cheap and
that may avoid the need for more invasive cardiovascular or
renal support.
5.Conclusions
Care must be taken when hyperinsulinaemia-euglycaemia is
used to avoid hypoglycaemia. A trial of metaraminol early
in severe cases of calcium channel blocker and angiotensin
II receptor antagonist toxicity may be of beneﬁt, especially
when conventional ionotropic treatment measures are fail-
ing.
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